Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s)…
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Novo Nordisk A/S Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders…
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Novo Nordisk A/S Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders…
Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase…
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Novo Nordisk A/S Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s)…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…
Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Novo Nordisk A/S Early responders (15% or more weight loss after 24 weeks) to the higher dose of…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…
Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026
Novo Nordisk A/S Bagsværd, Denmark, 6 May 2026 – Financial report for the period 1 January 2026 to…
Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share…